Indication
Bioavailability
9 clinical trials
13 products
Product
WCK 771Clinical trial
Phase-I, Double-blind, Randomized, Placebo-controlled Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771 in Adult Healthy Human VolunteersStatus: Completed, Estimated PCD: 2012-02-07
Product
IP2015Clinical trial
An Open-Label, Bioavailability Study to Compare Liquid vs Two Solid Formulations of IP2015 in Healthy Male SubjectsStatus: Not yet recruiting, Estimated PCD: 2023-05-16
Product
SorafenibClinical trial
A Single Part, Open-Label, Randomised, Three-Way Crossover Study Designed to Evaluate the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib From Sorafenib (XS005) Tablets and Capsules Compared With Nexavar® (Reference Product) in Healthy Male SubjectsStatus: Completed, Estimated PCD: 2019-02-12
Product
XS005 SorafenibClinical trial
A Randomized, Single Dose, Crossover Study in Healthy Volunteers to Investigate the Relative Bioavailability of Linaprazan for a New Oral Tablet Formulation of Linaprazan Glurate, and to Assess the Effect of Food on the Pharmacokinetics of LinaprazanStatus: Completed, Estimated PCD: 2022-12-30
Product
LinaprazanClinical trial
A Randomized, Open-label, 3-period, Single-dose, Cross-over Study in Healthy Adult Subjects to Assess the Relative Bioavailability of Filgotinib Given as an Oral Mini-tablet Formulation Versus the Oral Tablet Formulation of Filgotinib and to Assess the Effect of Food on the Oral Mini-tablet FormulationStatus: Completed, Estimated PCD: 2023-10-27
Product
FilgotinibClinical trial
A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PF-07321332/RITONAVIR ORAL POWDER IN 3 DIFFERENT DELIVERY VEHICLES RELATIVE TO THE COMMERCIAL PF-07321332/RITONAVIR TABLETS IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITIONSStatus: Completed, Estimated PCD: 2022-05-19
Product
PF-07321332/ritonavirClinical trial
An Open-label, Randomized, Single-dose, Two-period Cross-over Study to Evaluate the Relative Bioavailability Between BH006 for Injection Per the Intended Dosage Regimen and Fosaprepitant and Palonosetron in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-09-01
Product
BH006Product
FosaprepitantClinical trial
Curcumin and Retinal Amyloid-beta Pilot StudyStatus: Recruiting, Estimated PCD: 2025-03-31
Product
Low curcuminProduct
High curcuminClinical trial
A Pilot, Phase 1, Randomized, Open-Label, Single-Dose, Four-Way Crossover Study to Compare the Pharmacokinetics of Sapropterin Dihydrochloride 100 mg/mL Oral Suspension (Product Code: RLF-OD032) (Test) With Kuvan® (Sapropterin Dihydrochloride) 100 mg Powder for Oral Solution (Reference) and to Evaluate the Effect of Food and the Effect of Water on the Bioavailability of Sapropterin Dihydrochloride 100 mg/mL Oral Suspension in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-08-31
Product
RLF-OD032Product
Kuvan